Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer

Scientific Reports

Volumn 5, Issue 1, 2015, Pages

  Lei, Jun H ^a   Liu, Liang R ^a   Wei, Qiang ^a   Yan, Shi B ^b   Song, Tu R ^a   Lin, Fu S ^a   Yang, Lu ^a   Cao, De H ^a   Yuan, Hai C ^a   Xue, Wen B ^a   Lv, Xiao ^a   Cai, Ying C ^a   Zeng, Hao ^a   Han, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MALE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; WATCHFUL WAITING;

COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84944278724     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/SREP07713     Document Type: Article

References (37)

1. Bosetti, C. et al. Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 60, 1–15 (2011).
2. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28, 1117–23 (2010).
3. Bastian, P. J. et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 61, 1096–106 (2012).
4. D’Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969–74 (1998).
5. Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177, 2106–31 (2007).
6. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59, 61–71 (2011).
7. Roach, M. et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47, 609–15 (2000).
8. Abdollah, F. et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 63, 998–1008 (2013).
9. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12 (1996).
10. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta analyses. Eur J Epidemiol, 25, 603–5(2010).
11. Wells, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta analyses. , (2012 published), Date of access: 15/06/2012
12. Bolla, M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337, 295–300 (1997).
13. D’Amico, A. V. et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292, 821–827 (2004).
14. Pilepich, M. V. et al. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of RTOG Protocol 85–31. J Clin Oncol 15, 1013–1021 (1997).
15. Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50, 1243–1252 (2001).
16. Zelefsky, M. J. et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28, 1508–13 (2010).
17. Merino, T. et al. Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up. BMC Cancer 13, 530 (2013).
18. Tewari, A. et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach. J Urol 177, 911 (2007).
19. Kibel, A. S. et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187, 1259–65 (2012).
20. Stokes, S. H. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiation Oncology Biol Phys 47, 129–136 (2000).
21. Cooperberg, M. R., Vickers, A. J., Broering, J. M. & Carroll, P. R. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116, 5226–34 (2010).
22. Siddiqui, S. A. et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 107, 383–8 (2011).
23. Bastide, C. et al. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int 109, 525–32 (2011).
24. Koie, T. et al. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis. World Journal of Surgical Oncology 12, 134 (2014).
25. Lee, J. Y. et al. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer. Ann Surg Oncol 21, 4026–4033 (2014).
26. Hsu, C. Y. et al. Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. BJU Int 99, 311–14 (2006).
27. Westover, K. et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int 110, 1116–21 (2012).
28. Galalae, R. M. et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (hdr-bt) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiation Oncology Biol Phys 58, 1048–55 (2004).
29. Demanes, D. J. et al. Excellent Results From High Dose Rate Brachytherapy and External Beam for Prostate Cancer are Not Improved by Androgen Deprivation. Am J Clin Oncol 32, 342–347 (2009).
30. Bastian, P. J. et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 61, 1096–106 (2012).
31. Abdollah, F. et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol. 63, 998–1008 (2013).
32. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. 65, 124–37 (2014).
33. Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 177, 2106–31 (2007).
34. Mohler, J. L. et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 10, 1081–7 (2012).
35. Albertsen, P. C., Hanley, J. A. & Fine. J. 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 293, 2095–2101 (2005).
36. Lu-Yao, G. L. et al. Outcomes of localized prostate cancer following conservative management. JAMA 302, 1202–9 (2009).
37. Ward, J. F. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU int 95, 751–756 (2005).